| AASLD

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Read more about Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Kazuaki Chayama, Shoichi Takahashi, Joji Toyota, Yoshiyasu Karino, Kenji Ikeda, Hiroki Ishikawa, Hideaki Watanabe, Fiona McPhee, Eric Hughes, Hiromitsu Kumada – 10 October 2011 – Patients with chronic hepatitis C virus (HCV) infection and previous null response to pegylated interferon (Peg‐IFN) and ribavirin (RBV) have limited therapeutic options. HCV genotype 1 is the most common worldwide and the most difficult to treat; genotype 1b is the most common subtype of genotype 1 outside North America.

Impact of venous systemic oxygen persufflation supplemented with nitric oxide gas on cold‐stored, warm ischemia–damaged experimental liver grafts

Read more about Impact of venous systemic oxygen persufflation supplemented with nitric oxide gas on cold‐stored, warm ischemia–damaged experimental liver grafts

Pramod Kadaba Srinivasan, Shintaro Yagi, Benedict Doorschodt, Kazuyuki Nagai, Mamdouh Afify, Shinji Uemoto, Rene Tolba – 10 October 2011 – The increasing shortage of donor organs has led to the increasing use of organs from non–heart‐beating donors. We aimed to assess the impact of venous systemic oxygen persufflation (VSOP) supplemented with nitric oxide (NO) gas during the cold storage (CS) of warm ischemia (WI)–damaged experimental liver grafts.